CD19 and cancer: Of note, CD19+CD24hiIgDlo/−CD38hi Bregs from peripheral blood of both healthy subjects and cancer patients showed stronger suppression than CD19+CD24hiIgDlo/−CD38lo Bregs (Fig. 5e, right).